Zejula (niraparib)

The recently FDA approved, ZEJULA™ (Niraparib), is the first and only PARP inhibitor to be approved for the maintenance treatment of women with recurrent ovarian cancer. 

The challenges:

  • Entering medical drug market as a newly FDA approved product
  • Were not reaching supplementary readers within the target market
  • Specifi c budget limit with no room for overage
  • Limited access and information to medical conferences pertaining to ovarian and breast cancer